Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

Healthcare Biotechnology
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany. The Company is also focused on regulatory approval and commercialization of medical products for European markets. Its diagnostic products include COVID-19 PCR Diagnostic Kit, Peri-Implantitis Oral Biosensor, and H1N1 (Swine Flu) and H5N1 (Avian Flu) Oral Biosensors. Its subsidiaries include XPhyto Laboratories Inc., Bunker Pflanzenextrakte GmbH, Vektor Pharma TF GmbH, BioNxt Europe GmbH, and 3a-diagnostics GmbH, among others.


CSE:BNXT - Post by User

BioNxt Solutions Inc > Clock is ticking for rapid PCR test approval-Q1 2021
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by Adwarion Feb 06, 2021 8:47pm
266 Views
Post# 32494527

Clock is ticking for rapid PCR test approval-Q1 2021

Clock is ticking for rapid PCR test approval-Q1 2021XPhyto is in discussions to secure manufacturing and distribution partners in Europe and the Middle East in anticipation of pending commercial approval and product launch in Q1 2021.

Q1 2021 is January 1 to March 31, 2021.

The clock is ticking. I am holding tight to my shares. If they announce the approval of the test kit, Xphy is gonna fly. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities